The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Abstract

These results highlight important differences between specific Ex19Del mutations that may be relevant for optimizing TKI choice for patients.